Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE
Measuring anti-dsDNA levels could support treatment adjustment during follow-up of patients with systemic lupus erythematosus (SLE). We investigated whether patients with exacerbations of SLE showed changes in anti-double-stranded DNA (anti-dsDNA) levels prior to the exacerbation using the Farr and...
Gespeichert in:
| Veröffentlicht in: | Lupus 2013-10, Vol.22 (11), p.1169-1173 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1173 |
|---|---|
| container_issue | 11 |
| container_start_page | 1169 |
| container_title | Lupus |
| container_volume | 22 |
| creator | Hillebrand, JJG Moens, HJ Bernelot Mulder, AHL |
| description | Measuring anti-dsDNA levels could support treatment adjustment during follow-up of patients with systemic lupus erythematosus (SLE). We investigated whether patients with exacerbations of SLE showed changes in anti-double-stranded DNA (anti-dsDNA) levels prior to the exacerbation using the Farr and EliA assay and examined which assay showed highest specificity and predictive value for exacerbations. Changes in anti-dsDNA of ≥25% prior to exacerbation were considered of clinical significance. Exacerbations were retrospectively abstracted from medical records. Eighteen of 48 patients showed one or more exacerbations. We found 22 exacerbations with complete lab work-up, all accompanied by ≥25% change in anti-dsDNA in one or both assays. Only 10 exacerbations showed concordant changes in anti-dsDNA in both assays. Changes in anti-dsDNA had a low predictive value for exacerbations of SLE, but the specificity of anti-dsDNA changes for patients with exacerbations was higher for EliA than Farr. We conclude that despite the limited relation between anti-dsDNA changes and exacerbations of SLE, anti-dsDNA testing could still support clinical decision making when used in the correct setting. We conclude that EliA is preferable over Farr for assaying anti-dsDNA during follow-up of patients with SLE because of higher specificity, less “hands-on” time and absence of radioactivity. |
| doi_str_mv | 10.1177/0961203313500368 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1439221424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0961203313500368</sage_id><sourcerecordid>1435851069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-9fe2bfbb5ac22eec1830d0e1761a9870f300dfdc2e2ee9caeff6577d6ccdbb953</originalsourceid><addsrcrecordid>eNqNkc9r2zAUx8VYWdJs952KYJde3OqHLVnHkKU_IHSHtWcjS0-Zg22lkg3rf1-ZZGMLFHoST9_P-z7pfRH6SskVpVJeEyUoI5xTXhDCRfkBzWkuZZbu2Uc0n-Rs0mfoPMYdSQxV4hOaMa6YEryco_3ql-63EHHT4xsdAg7aNr7purH3Okb9gnVv8bptlti1ow8QDfQG8P_E0GQ2fn9YTi4BWj00vseDx_BbGwj1ofYO_9ysP6Mzp9sIX47nAj3drB9Xd9nmx-39arnJDFflkCkHrHZ1XWjDGIChJSeWAJWCalVK4jgh1lnDIKnKaHBOFFJaYYyta1XwBbo8-O6Dfx4hDlXXpLe3re7Bj7GiedoBoznL34MWZUGJUAn9doLu_Bj69JGJyqUgZT4ZkgNlgo8xgKv2oel0eKkoqabgqtPgUsvF0XisO7B_G_4klYDsAES9hX-mvmX4CuoKoEc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1434760844</pqid></control><display><type>article</type><title>Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Hillebrand, JJG ; Moens, HJ Bernelot ; Mulder, AHL</creator><creatorcontrib>Hillebrand, JJG ; Moens, HJ Bernelot ; Mulder, AHL</creatorcontrib><description>Measuring anti-dsDNA levels could support treatment adjustment during follow-up of patients with systemic lupus erythematosus (SLE). We investigated whether patients with exacerbations of SLE showed changes in anti-double-stranded DNA (anti-dsDNA) levels prior to the exacerbation using the Farr and EliA assay and examined which assay showed highest specificity and predictive value for exacerbations. Changes in anti-dsDNA of ≥25% prior to exacerbation were considered of clinical significance. Exacerbations were retrospectively abstracted from medical records. Eighteen of 48 patients showed one or more exacerbations. We found 22 exacerbations with complete lab work-up, all accompanied by ≥25% change in anti-dsDNA in one or both assays. Only 10 exacerbations showed concordant changes in anti-dsDNA in both assays. Changes in anti-dsDNA had a low predictive value for exacerbations of SLE, but the specificity of anti-dsDNA changes for patients with exacerbations was higher for EliA than Farr. We conclude that despite the limited relation between anti-dsDNA changes and exacerbations of SLE, anti-dsDNA testing could still support clinical decision making when used in the correct setting. We conclude that EliA is preferable over Farr for assaying anti-dsDNA during follow-up of patients with SLE because of higher specificity, less “hands-on” time and absence of radioactivity.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203313500368</identifier><identifier>PMID: 23929638</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adolescent ; Adult ; Aged ; Antibodies, Antinuclear - blood ; Automation ; Enzymes ; Female ; Fluorescent Antibody Technique - methods ; Humans ; Immunoassay ; Laboratories ; Lupus ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - immunology ; Male ; Medical records ; Middle Aged ; Radioimmunoassay - methods ; Retrospective Studies ; Rheumatology ; Test systems</subject><ispartof>Lupus, 2013-10, Vol.22 (11), p.1169-1173</ispartof><rights>The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</rights><rights>SAGE Publications © Oct 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-9fe2bfbb5ac22eec1830d0e1761a9870f300dfdc2e2ee9caeff6577d6ccdbb953</citedby><cites>FETCH-LOGICAL-c398t-9fe2bfbb5ac22eec1830d0e1761a9870f300dfdc2e2ee9caeff6577d6ccdbb953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0961203313500368$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0961203313500368$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23929638$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hillebrand, JJG</creatorcontrib><creatorcontrib>Moens, HJ Bernelot</creatorcontrib><creatorcontrib>Mulder, AHL</creatorcontrib><title>Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Measuring anti-dsDNA levels could support treatment adjustment during follow-up of patients with systemic lupus erythematosus (SLE). We investigated whether patients with exacerbations of SLE showed changes in anti-double-stranded DNA (anti-dsDNA) levels prior to the exacerbation using the Farr and EliA assay and examined which assay showed highest specificity and predictive value for exacerbations. Changes in anti-dsDNA of ≥25% prior to exacerbation were considered of clinical significance. Exacerbations were retrospectively abstracted from medical records. Eighteen of 48 patients showed one or more exacerbations. We found 22 exacerbations with complete lab work-up, all accompanied by ≥25% change in anti-dsDNA in one or both assays. Only 10 exacerbations showed concordant changes in anti-dsDNA in both assays. Changes in anti-dsDNA had a low predictive value for exacerbations of SLE, but the specificity of anti-dsDNA changes for patients with exacerbations was higher for EliA than Farr. We conclude that despite the limited relation between anti-dsDNA changes and exacerbations of SLE, anti-dsDNA testing could still support clinical decision making when used in the correct setting. We conclude that EliA is preferable over Farr for assaying anti-dsDNA during follow-up of patients with SLE because of higher specificity, less “hands-on” time and absence of radioactivity.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antibodies, Antinuclear - blood</subject><subject>Automation</subject><subject>Enzymes</subject><subject>Female</subject><subject>Fluorescent Antibody Technique - methods</subject><subject>Humans</subject><subject>Immunoassay</subject><subject>Laboratories</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Male</subject><subject>Medical records</subject><subject>Middle Aged</subject><subject>Radioimmunoassay - methods</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Test systems</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkc9r2zAUx8VYWdJs952KYJde3OqHLVnHkKU_IHSHtWcjS0-Zg22lkg3rf1-ZZGMLFHoST9_P-z7pfRH6SskVpVJeEyUoI5xTXhDCRfkBzWkuZZbu2Uc0n-Rs0mfoPMYdSQxV4hOaMa6YEryco_3ql-63EHHT4xsdAg7aNr7purH3Okb9gnVv8bptlti1ow8QDfQG8P_E0GQ2fn9YTi4BWj00vseDx_BbGwj1ofYO_9ysP6Mzp9sIX47nAj3drB9Xd9nmx-39arnJDFflkCkHrHZ1XWjDGIChJSeWAJWCalVK4jgh1lnDIKnKaHBOFFJaYYyta1XwBbo8-O6Dfx4hDlXXpLe3re7Bj7GiedoBoznL34MWZUGJUAn9doLu_Bj69JGJyqUgZT4ZkgNlgo8xgKv2oel0eKkoqabgqtPgUsvF0XisO7B_G_4klYDsAES9hX-mvmX4CuoKoEc</recordid><startdate>201310</startdate><enddate>201310</enddate><creator>Hillebrand, JJG</creator><creator>Moens, HJ Bernelot</creator><creator>Mulder, AHL</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>7TM</scope></search><sort><creationdate>201310</creationdate><title>Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE</title><author>Hillebrand, JJG ; Moens, HJ Bernelot ; Mulder, AHL</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-9fe2bfbb5ac22eec1830d0e1761a9870f300dfdc2e2ee9caeff6577d6ccdbb953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antibodies, Antinuclear - blood</topic><topic>Automation</topic><topic>Enzymes</topic><topic>Female</topic><topic>Fluorescent Antibody Technique - methods</topic><topic>Humans</topic><topic>Immunoassay</topic><topic>Laboratories</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Male</topic><topic>Medical records</topic><topic>Middle Aged</topic><topic>Radioimmunoassay - methods</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Test systems</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hillebrand, JJG</creatorcontrib><creatorcontrib>Moens, HJ Bernelot</creatorcontrib><creatorcontrib>Mulder, AHL</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hillebrand, JJG</au><au>Moens, HJ Bernelot</au><au>Mulder, AHL</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2013-10</date><risdate>2013</risdate><volume>22</volume><issue>11</issue><spage>1169</spage><epage>1173</epage><pages>1169-1173</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Measuring anti-dsDNA levels could support treatment adjustment during follow-up of patients with systemic lupus erythematosus (SLE). We investigated whether patients with exacerbations of SLE showed changes in anti-double-stranded DNA (anti-dsDNA) levels prior to the exacerbation using the Farr and EliA assay and examined which assay showed highest specificity and predictive value for exacerbations. Changes in anti-dsDNA of ≥25% prior to exacerbation were considered of clinical significance. Exacerbations were retrospectively abstracted from medical records. Eighteen of 48 patients showed one or more exacerbations. We found 22 exacerbations with complete lab work-up, all accompanied by ≥25% change in anti-dsDNA in one or both assays. Only 10 exacerbations showed concordant changes in anti-dsDNA in both assays. Changes in anti-dsDNA had a low predictive value for exacerbations of SLE, but the specificity of anti-dsDNA changes for patients with exacerbations was higher for EliA than Farr. We conclude that despite the limited relation between anti-dsDNA changes and exacerbations of SLE, anti-dsDNA testing could still support clinical decision making when used in the correct setting. We conclude that EliA is preferable over Farr for assaying anti-dsDNA during follow-up of patients with SLE because of higher specificity, less “hands-on” time and absence of radioactivity.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>23929638</pmid><doi>10.1177/0961203313500368</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 2013-10, Vol.22 (11), p.1169-1173 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1439221424 |
| source | MEDLINE; SAGE Complete |
| subjects | Adolescent Adult Aged Antibodies, Antinuclear - blood Automation Enzymes Female Fluorescent Antibody Technique - methods Humans Immunoassay Laboratories Lupus Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - immunology Male Medical records Middle Aged Radioimmunoassay - methods Retrospective Studies Rheumatology Test systems |
| title | Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T08%3A09%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20Farr%20radioimmunoassay%20and%20EliA%20fluorescence%20immunoassay%20anti-dsDNA%20in%20relation%20to%20exacerbation%20of%20SLE&rft.jtitle=Lupus&rft.au=Hillebrand,%20JJG&rft.date=2013-10&rft.volume=22&rft.issue=11&rft.spage=1169&rft.epage=1173&rft.pages=1169-1173&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203313500368&rft_dat=%3Cproquest_cross%3E1435851069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1434760844&rft_id=info:pmid/23929638&rft_sage_id=10.1177_0961203313500368&rfr_iscdi=true |